Sequencing BTK Inhibitors and Managing Cardiac Toxicities in Mantle Cell Lymphoma

Today’s podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Craig Portell, MD, University of Virginia, Charlottesville, VA. They share updates on trials investigating BTKis in the frontline treatment of MCL, including the ECHO (NCT02972840), SHINE (NCT01776840), and TRIANGLE (NCT02858258) studies. They then go on to discuss how these agents are optimally sequenced and give advice for managing cardiac toxicities associated with BTKis.  

The post Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events appeared first on VJHemOnc.